September 28, 2021 10:45 UTC
KENILWORTH, New Jersey – (COMMERCIAL THREAD) – Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third quarter 2021 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday October 28. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.
Investors, journalists and the general public can access a live audio webcast of the call on Merck’s website at https://www.merck.com/investor-relations/events-and-presentations/. A replay of the webcast, along with the sales and earnings press release and additional financial information and slides highlighting the results, will be available at www.merck.com.
Institutional investors and analysts can participate in the call by dialing (833) 353-0277 or (469) 886-1947 and using the ID code 6768456. Members of the media are encouraged to follow the call by dialing (833) 353-0277 or (469) 886-1947 and using the ID code 6768456. Journalists wishing to ask questions should contact a member of the media relations team of Merck at the end of the call.
For more than 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, providing drugs and vaccines for many of the world’s most difficult diseases as part of our mission to save and improve lives. We demonstrate our commitment to patients and the health of the population by increasing access to health care through broad policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company. in the world. For more information visit www.merck.com and connect with us on Twitter, Facebook, Instagram, Youtube and LinkedIn.
Forward-looking statement by Merck & Co., Inc., Kenilworth, NJ, United States
This press release from Merck & Co., Inc., Kenilworth, NJ, United States (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act. from 1995. These statements are based on the current beliefs and expectations of the management of the company and are subject to significant risks and uncertainties. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including fluctuations in interest rates and exchange rates; the impact of the global novel coronavirus disease (COVID-19) epidemic; the impact of pharmaceutical industry regulation and health care legislation in the United States and globally; global trends towards containing health care costs; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of patents and other corporate protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions.
The company does not undertake to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in forward-looking statements can be found in the company’s 2020 annual report on Form 10-K and other documents filed by the company with the Securities. and Exchange Commission (SEC) available from the SEC. Website (www.sec.gov).
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210928005210/en/